


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A compound of formula (I):



(I)

wherein

A is a fused 5-membered heteroaryl ring selected from an isoxazolyl ring, a pyrrolyl or a thiazolyl ring, which ring is optionally substituted by up to two substituents independently selected from C₁₋₆alkyl, -(CH₂)_m-C₃₋₇cycloalkyl, halogen, cyano, trifluoromethyl, -(CH₂)_mOR³, -(CH₂)_mCO₂R³, -(CH₂)_mNR³R⁴, -(CH₂)_mCONR³R⁴, -(CH₂)_mNHCOR³, -(CH₂)_mSO₂NR³R⁴, -(CH₂)_mNHSO₂R³, -(CH₂)_mSO₂(CH₂)_nR⁵, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C₁₋₂alkyl or -(CH₂)_mCO₂R³, and a 5-membered heteroaryl ring optionally substituted by C₁₋₂alkyl;

R¹ is selected from methyl and chloro;

R² is selected from -NH-CO-R⁶ and -CO-NH-(CH₂)_q-R⁷;

R³ is selected from hydrogen, C₁₋₆alkyl optionally substituted by up to two OH groups, -(CH₂)_m-C₃₋₇cycloalkyl, -(CH₂)_mphenyl optionally substituted by R⁸ and/or R⁹ and -(CH₂)_mheteroaryl optionally substituted by R⁸ and/or R⁹ [[,]];

R⁴ is selected from hydrogen and C₁₋₆alkyl, or

R³ and R⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

R⁵ is selected from C₁₋₆alkyl optionally substituted by up to three halogen atoms, C₂₋₆alkenyl optionally substituted by phenyl, C₃₋₇cycloalkyl, heteroaryl optionally substituted by up to three R⁸ and/or R⁹ groups, and phenyl optionally substituted by R⁸ and/or R⁹;

R⁶ is selected from hydrogen, C₁₋₆alkyl, -(CH₂)_q-C₃₋₇cycloalkyl, trifluoromethyl, -(CH₂)_rheteroaryl optionally substituted by R¹¹ and/or R¹², and -(CH₂)_rphenyl optionally substituted by R¹¹ and/or R¹²;

R⁷ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, -CONHR¹³, phenyl optionally substituted by R¹¹ and/or R¹², and heteroaryl optionally substituted by R¹¹ and/or R¹²;

R⁸ and R⁹ are each independently selected from halogen, cyano, trifluoromethyl, nitro, C₁₋₆alkyl, C₁₋₆alkoxy, -CONR¹³R¹⁴, -COR¹⁵, -CO₂R¹⁵, and heteroaryl, or

R⁸ and R⁹ are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and N-R¹⁰, or a fused heteroaryl ring;

R¹⁰ is selected from hydrogen and methyl;

R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_q-C₃₋₇cycloalkyl, -CONR¹³R¹⁴, -NHCOR¹⁴, halogen, CN, -(CH₂)_sNR¹⁶R¹⁷, trifluoromethyl, phenyl optionally substituted by one or more R¹² groups, and heteroaryl optionally substituted by one or more R¹² groups;

R¹² is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, and -(CH₂)_sNR¹⁶R¹⁷;

R¹³ and R¹⁴ are each independently selected from hydrogen and C₁₋₆alkyl, or

R¹³ and R¹⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰, wherein the ring may be substituted by up to two C₁₋₆alkyl groups;

R¹⁵ is C₁₋₆alkyl;

R¹⁶ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_q-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁷ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁶ and R¹⁷, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

X and Y are each independently selected from hydrogen, methyl and halogen;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

2 (currently amended). A compound according to claim 1 wherein A is ~~a fused 5-membered heteroaryl ring containing up to two heteroatoms independently selected from oxygen and nitrogen~~ optionally substituted by up to two substituents independently selected from C₁₋₄alkyl, -(CH₂)_m-C₃₋₇cycloalkyl, -(CH₂)_mCO₂R³, -(CH₂)_mNR³R⁴, -(CH₂)_mCONR³R⁴, -(CH₂)_mNHCOR³, -(CH₂)_mSO₂(CH₂)_nR⁵, and a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C₁₋₂alkyl or -(CH₂)_mCO₂R³.

3 (previously presented). A compound according to claim 1 wherein R¹ is methyl.

4 (previously presented). A compound according to claim 1 wherein R² is -CO-NH-(CH₂)_q-R⁷.

5 (previously presented). A compound according to claim 1 wherein X is hydrogen or fluorine.

6 (Previously presented). A compound according to claim 1 which is:

N-Cyclopropyl-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-N-(3-morpholin-4-ylphenyl)-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(3-morpholin-4-ylphenyl)benzamide;

4-Methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-(3-methyl-1,2-benzisoxazol-6-yl)benzamide;


or a pharmaceutically acceptable salt thereof.

7 (previously presented). A pharmaceutical composition comprising a compound according to claim 1 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

8. and 9. (Cancelled)


10 (previously presented). A process for preparing a compound of formula (I) according to claim 1 which comprises

(a) reacting a compound of formula (II)




(II)

in which A is defined in claim 1 and Z¹ is halogen,
with a compound of formula (IIIA) or (IIIB)



(IIIA)




(IIIB)

in which R^1 , R^2 , X and Y are as defined in claim 1,
in the presence of a catalyst, or

(b) final stage modification of one compound of formula (I) as defined in claim 1 to give another compound of formula (I) as defined in claim 1.

11 (currently amended). A compound of formula (IA):



(IA)

wherein

A is a fused 5-membered heteroaryl ring selected from an isoxazolyl ring, a pyrrolyl or a thiazolyl ring, which ring is optionally substituted by up to two substituents independently selected from C_{1-6} alkyl, $-(CH_2)_m-C_{3-7}$ cycloalkyl, halogen, cyano, trifluoromethyl, $-(CH_2)_mOR^3$, $-(CH_2)_mNR^3R^4$, $-(CH_2)_mCONR^3R^4$, $-(CH_2)_mNHCOR^3$, $-(CH_2)_mSO_2NR^3R^4$, $-(CH_2)_mNHSO_2R^3$, $-(CH_2)_mSO_2(CH_2)_nR^5$, a 5- or 6-membered heterocyclyl ring containing nitrogen optionally substituted by C_{1-2} alkyl and a 5-membered heteroaryl ring optionally substituted by C_{1-2} alkyl;

R^1 is selected from methyl and chloro;

R^2 is selected from $-NH-CO-R^6$ and $-CO-NH-(CH_2)_q-R^7$;

R^3 is selected from hydrogen, C_{1-6} alkyl optionally substituted by up to two OH groups, $-(CH_2)_m-C_{3-7}$ cycloalkyl, $-(CH_2)_m$ phenyl optionally substituted by R^8 and/or R^9 and $-(CH_2)_m$ heteroaryl optionally substituted by R^8 and/or R^9

R^4 is selected from hydrogen and C_{1-6} alkyl, or

R³ and R⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

R⁵ is selected from C₁₋₆alkyl, C₃₋₇cycloalkyl, heteroaryl optionally substituted by R⁸ and/or R⁹, and phenyl optionally substituted by R⁸ and/or R⁹;

R⁶ is selected from hydrogen, C₁₋₆alkyl, -(CH₂)_q-C₃₋₇cycloalkyl, trifluoromethyl, -(CH₂)_rheteroaryl optionally substituted by R¹¹ and/or R¹², and -(CH₂)_rphenyl optionally substituted by R¹¹ and/or R¹²;

R⁷ is selected from hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, CONHR¹³, phenyl optionally substituted by R¹¹ and/or R¹², and heteroaryl optionally substituted by R¹¹ and/or R¹²;

R⁸ and R⁹ are each independently selected from halogen, cyano, trifluoromethyl, C₁₋₆alkyl, C₁₋₆alkoxy, COR¹⁵, CO₂R¹⁵, and heteroaryl, or

R⁸ and R⁹ are linked to form a fused 5-membered heterocyclyl ring containing one heteroatom selected from oxygen, sulphur and N-R¹⁰;

R¹⁰ is selected from hydrogen and methyl;

R¹¹ is selected from C₁₋₆alkyl, C₁₋₆alkoxy, -(CH₂)_q-C₃₋₇cycloalkyl, -CONR¹³R¹⁴, -NHCOR¹⁴, halogen, CN, -(CH₂)_sNR¹⁶R¹⁷, trifluoromethyl, phenyl optionally substituted by one or more R¹² groups, and heteroaryl optionally substituted by one or more R¹² groups;

R¹² is selected from C₁₋₆alkyl, C₁₋₆alkoxy, halogen, trifluoromethyl, and -(CH₂)_sNR¹⁶R¹⁷;

R¹³ and R¹⁴ are each independently selected from hydrogen and C₁₋₆alkyl, or

R¹³ and R¹⁴, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰, wherein the ring may be substituted by up to two C₁₋₆alkyl groups;

R¹⁵ is C₁₋₆alkyl;

R¹⁶ is selected from hydrogen, C₁₋₆alkyl and -(CH₂)_q-C₃₋₇cycloalkyl optionally substituted by C₁₋₆alkyl,

R¹⁷ is selected from hydrogen and C₁₋₆alkyl, or

R¹⁶ and R¹⁷, together with the nitrogen atom to which they are bound, form a 5- or 6-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen, sulfur and N-R¹⁰;

m is selected from 0, 1, 2 and 3;

n is selected from 0, 1, 2 and 3;

q is selected from 0, 1 and 2;

r is selected from 0 and 1; and

s is selected from 0, 1, 2 and 3.

12 (currently amended). A compound according to claim 1 which is:

N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

~~N-cyclopropyl-4-methyl-3-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-{1-[(3-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;~~

~~N-cyclopropyl-4-methyl-3-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-{1-[(4-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;~~

N-cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

~~N-cyclopropyl-4-methyl-3-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl}benzamide);~~

~~N-cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;~~

~~N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-4-methylbenzamide;~~

~~N-cyclopropyl-4-methyl-3-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;~~

3-{1-[(2-cyanophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-4-methylbenzamide;

~~N-cyclopropyl-3-fluoro-4-methyl-5-[1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-[1-(3-thienylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(1-methylethyl)sulfonyl]-1H-indazol-5-yl}benzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-[1-(propylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-[1-(methylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~3-[1-(butylsulfonyl)-1H-indazol-5-yl]-N-cyclopropyl-5-fluoro-4-methylbenzamide;~~

~~N-cyclopropyl-3-[1-(cyclopropylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;~~

~~3-{1-[(5-chloro-2-thienyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;~~

~~N-cyclopropyl-3-{1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;~~

~~N-cyclopropyl-3-[1-(ethylsulfonyl)-1H-indazol-5-yl]-5-fluoro-4-methylbenzamide;~~

~~3-{1-[(2-chlorophenyl)sulfonyl]-1H-indazol-5-yl}-N-cyclopropyl-5-fluoro-4-methylbenzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-{1-[(2-methylphenyl)sulfonyl]-1H-indazol-5-yl}benzamide;~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indazol-5-yl]benzamide;~~

~~N-cyclopropyl-3-{1-[(2,5-difluorophenyl)sulfonyl]-1H-indazol-5-yl}-5-fluoro-4-methylbenzamide;~~

~~N-cyclopropyl-3-fluoro-5-{1-[(2-fluorophenyl)sulfonyl]-1H-indazol-5-yl}-4-methylbenzamide;~~

~~N-cyclopropyl-3-[1-(cyclopropylmethyl)-1H-indazol-5-yl]-4-methylbenzamide; or~~

~~N-cyclopropyl-3-fluoro-4-methyl-5-[3-methyl-1-(2-thienylsulfonyl)-1H-indazol-5-yl]benzamide; or a pharmaceutically acceptable salt thereof.~~

13. (cancelled)

14. (cancelled)

15. (withdrawn). A compound according to claim 1 which is:

N-[4-Methyl-3-(3-methyl-1,2-benzisoxazol-5-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide;

N-Cyclopropyl-3-[3-({[2-hydroxy-1-(hydroxymethyl)ethyl]amino}methyl)-1,2-benzisoxazol-6-yl]-4-methylbenzamide;

N-(3-Methoxyphenyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3,4-thiadiazol-2-yl)benzamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]thiophene-3-carboxamide;

N-[4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-3-furamide;

N-(Cyclopropylmethyl)-4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)benzamide;

or a pharmaceutically acceptable salt thereof.

16. (cancelled)

17. (withdrawn) A compound according to Claim 1 which is

4-Methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)-N-(1,3-thiazol-2-yl)benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperazinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperazinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

Methyl (6-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-1,2-benzisoxazol-3-yl)acetate;

N-Cyclopropyl-3-(3-{2-[(2-hydroxyethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-piperidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(methylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-(3-{2-[(3-hydroxypropyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-3-(3-{2-[(cyclopropylmethyl)amino]-2-oxoethyl}-1,2-benzisoxazol-6-yl)-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-3-{3-[2-(ethylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-3-{3-[2-(cyclopropylamino)-2-oxoethyl]-1,2-benzisoxazol-6-yl}-4-methylbenzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-(4-morpholinyl)-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-({3-(methyloxy)phenyl}methyl)amino]-2-oxoethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[2-oxo-2-(1,3-thiazol-2-ylamino)ethyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-{3-[(4-methyl-1-piperazinyl)methyl]-1,2-benzisoxazol-6-yl}benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-piperidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(4-morpholinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

N-Cyclopropyl-4-methyl-3-[3-(1-pyrrolidinylmethyl)-1,2-benzisoxazol-6-yl]benzamide;

3-(3-Amino-1,2-benzisoxazol-6-yl)-N-cyclopropyl-4-methylbenzamide;

N-Cyclopropyl-3-[3-(cyclopropylamino)-1,2-benzisoxazol-6-yl]-5-fluoro-4-methylbenzamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-(cyclopropylmethyl)-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-propyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N-methyl-1,2-benzisoxazole-3-carboxamide;

6-{5-[(Cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-N,N-dimethyl-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-6-{5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl}-1,2-benzisoxazole-3-carboxamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-{1-[(4-methylphenyl)sulfonyl]-1H-indol-5-yl}benzamide;

N-Cyclopropyl-3-fluoro-4-methyl-5-[1-(phenylsulfonyl)-1H-indol-5-yl]benzamide;

N-Cyclopropyl-3-{2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}-4-methylbenzamide; or a pharmaceutically acceptable salt thereof.

18.(cancelled)

19. (cancelled)

20. (withdrawn) A pharmaceutical composition comprising a compound according to claim 6 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

21. (withdrawn) A pharmaceutical composition comprising a compound according to claim 12 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

22. (withdrawn) A pharmaceutical composition comprising a compound according to claim 15 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

23. (cancelled)

24. (withdrawn) A pharmaceutical composition comprising a compound according to claim 17 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

25. (cancelled)

26. (cancelled)